CN110831668B - 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗 - Google Patents

与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗 Download PDF

Info

Publication number
CN110831668B
CN110831668B CN201880041573.5A CN201880041573A CN110831668B CN 110831668 B CN110831668 B CN 110831668B CN 201880041573 A CN201880041573 A CN 201880041573A CN 110831668 B CN110831668 B CN 110831668B
Authority
CN
China
Prior art keywords
plasminogen
pai
subject
overexpression
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880041573.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110831668A (zh
Inventor
L·加尼翁
B·格劳克斯
P·劳伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promethico Biotherapy
Original Assignee
Promethico Biotherapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promethico Biotherapy filed Critical Promethico Biotherapy
Publication of CN110831668A publication Critical patent/CN110831668A/zh
Application granted granted Critical
Publication of CN110831668B publication Critical patent/CN110831668B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880041573.5A 2017-06-23 2018-06-22 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗 Active CN110831668B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
US62/523,901 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Publications (2)

Publication Number Publication Date
CN110831668A CN110831668A (zh) 2020-02-21
CN110831668B true CN110831668B (zh) 2024-04-12

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880041573.5A Active CN110831668B (zh) 2017-06-23 2018-06-22 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗

Country Status (20)

Country Link
US (1) US11826404B2 (enExample)
EP (1) EP3641888B1 (enExample)
JP (1) JP2020524689A (enExample)
KR (1) KR20200019217A (enExample)
CN (1) CN110831668B (enExample)
AU (1) AU2018287316B2 (enExample)
BR (1) BR112019027229A2 (enExample)
CA (1) CA3068153A1 (enExample)
CL (1) CL2019003789A1 (enExample)
DK (1) DK3641888T3 (enExample)
ES (1) ES2965937T3 (enExample)
FI (1) FI3641888T3 (enExample)
IL (1) IL271470B2 (enExample)
MX (1) MX2019015741A (enExample)
MY (1) MY203136A (enExample)
RU (1) RU2020100080A (enExample)
SG (1) SG11201912813SA (enExample)
TW (1) TWI868051B (enExample)
WO (1) WO2018234861A1 (enExample)
ZA (1) ZA202000280B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TW201822809A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療高脂血症的方法
EP4094775A4 (en) * 2020-02-06 2023-04-19 Talengen International Limited METHODS AND MEDICATIONS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS
JP2023518563A (ja) * 2020-03-24 2023-05-02 タレンゲン インターナショナル リミテッド パーキンソン病を治療する方法及び薬剤
TW202143999A (zh) * 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物
WO2021190558A1 (zh) * 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗阿尔茨海默病的方法和药物
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631786A1 (en) * 1993-07-02 1995-01-04 IMMUNO Aktiengesellschaft Lys - plasminogen in the prevention and treatment of ischemia and reperfusian injury
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
CN110121358A (zh) * 2016-12-15 2019-08-13 泰伦基国际有限公司 一种预防和治疗肺纤维化的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677473B1 (en) * 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
EP2056865B1 (en) * 2006-08-28 2013-12-25 Omnio Healer AB Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
CN101573134B (zh) * 2006-08-28 2013-03-06 李季男 抗感染候选药物
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
WO2018108161A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
CA3047170A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631786A1 (en) * 1993-07-02 1995-01-04 IMMUNO Aktiengesellschaft Lys - plasminogen in the prevention and treatment of ischemia and reperfusian injury
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
CN110121358A (zh) * 2016-12-15 2019-08-13 泰伦基国际有限公司 一种预防和治疗肺纤维化的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Development of Bleomycin-Induced Pulmonary Fibrosis in Mice Deficient for Components of the Fibrinolytic System;Zhenhua Zhou 等;《AMERICAN JOURNAL OF PATHOLOG》;第157卷(第157期);177-187 *

Also Published As

Publication number Publication date
CN110831668A (zh) 2020-02-21
WO2018234861A1 (en) 2018-12-27
EP3641888B1 (en) 2023-10-11
KR20200019217A (ko) 2020-02-21
IL271470B2 (en) 2025-07-01
MY203136A (en) 2024-06-10
RU2020100080A (ru) 2021-07-23
SG11201912813SA (en) 2020-01-30
DK3641888T3 (da) 2024-01-02
AU2018287316B2 (en) 2024-09-19
TWI868051B (zh) 2025-01-01
FI3641888T3 (fi) 2023-12-19
US11826404B2 (en) 2023-11-28
BR112019027229A2 (pt) 2020-07-07
IL271470B1 (en) 2025-03-01
CL2019003789A1 (es) 2020-07-10
RU2020100080A3 (enExample) 2021-11-02
MX2019015741A (es) 2020-11-11
ES2965937T3 (es) 2024-04-17
JP2020524689A (ja) 2020-08-20
TW201904990A (zh) 2019-02-01
ZA202000280B (en) 2021-08-25
CA3068153A1 (en) 2018-12-27
IL271470A (en) 2020-01-30
US20210330761A1 (en) 2021-10-28
AU2018287316A1 (en) 2020-02-06
EP3641888A1 (en) 2020-04-29
EP3641888A4 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
CN110831668B (zh) 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗
Zhu et al. MMP-9 inhibition alleviates postoperative cognitive dysfunction by improving glymphatic function via regulating AQP4 polarity
CA3152346A1 (en) Methods of treatment for modifying hemodynamics
JP6110587B2 (ja) 腹膜癒着防止用医薬組成物
KR20170045195A (ko) 대상체에서의 혈관신생을 유도하기 위한 10000Da 미만의 평균 분자량을 가지는 황산덱스트란의 용도
EP4471154A1 (en) Use of kinin or derivative thereof in treating vci, psci, or csvd
EP3299382B1 (en) Oligopeptide having proinflammatory cytokine secretion-inhibiting activity
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
CN110511266B (zh) 一种小分子多肽及其用途
ZA200504774B (en) Method of treatment of myocardial infarction
HK40029531A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
HK40029531B (en) Plasminogen treatment of conditions associated with pai-1 overexpression
WO2019048898A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
JP6289511B2 (ja) 羊水塞栓の治療剤
WO2017048157A1 (ru) Комбинаторная терапия для лечения геморрагического шока и последствий черепно-мозговой травмы
CN120501842A (zh) 直肠肽联合五羟二苯基酮对肾脏纤维化的协同改善作用
WO2006022281A1 (ja) コラーゲンまたはエラスチン代謝異常疾患の予防剤および治療剤
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
CN113301907A (zh) 用于治疗和/或改善伴有凝血障碍的败血症的药物
JP2007051086A (ja) コラーゲンまたはエラスチン代謝異常疾患の予防剤および治療剤
JP2007262027A (ja) Ａｔ−ｉｉｉによる内因性ｉｇｆ−１の産生誘導剤
HK1196289B (en) Medicine for treatment and/or improvement of sepsis
HK1196289A1 (zh) 用於败血症的治疗和/或改善的药物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant